These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 8800119)

  • 1. Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators.
    Stevens SK; Haffajee CI; Naccarelli GV; Schwartz KM; Luceri RM; Packer DL; Rubin AM; Kowey PR
    J Am Coll Cardiol; 1996 Aug; 28(2):418-22. PubMed ID: 8800119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active Can Investigators.
    Bardy GH; Yee R; Jung W
    J Am Coll Cardiol; 1996 Aug; 28(2):400-10. PubMed ID: 8800117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of the effect of biphasic waveform defibrillation on ventricular pacing thresholds.
    Kudenchuk PJ; Poole JE; Dolack GL; Gleva MJ; Anderson J; Troutman C; Bardy GH
    J Cardiovasc Electrophysiol; 1997 May; 8(5):485-95. PubMed ID: 9160224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg).
    Siebels J; Kuck KH
    Am Heart J; 1994 Apr; 127(4 Pt 2):1139-44. PubMed ID: 8160593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of chronic oral moricizine and intravenous epinephrine on ventricular fibrillation and defibrillation thresholds.
    Pharand C; Goldman R; Fan C; Chow M; Kluger J
    Pacing Clin Electrophysiol; 1996 Jan; 19(1):82-9. PubMed ID: 8848382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of defibrillation efficacy using implantable cardioverter-defibrillator with single- or dual-coil defibrillation leads and active can.
    Lubiński A; Lewicka-Nowak E; Zienciuk A; Królak T; Kempa M; Pazdyga A; Raczak G; Swiatecka G
    Kardiol Pol; 2005 Sep; 63(3):234-41; discussion 242-3. PubMed ID: 16180177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with a new cardioverter defibrillator capable of biphasic waveform pulse and enhanced data storage: results of a prospective multicenter study. European Ventak P2 Investigator Group.
    Neuzner J
    Pacing Clin Electrophysiol; 1994 Jul; 17(7):1243-55. PubMed ID: 7937230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reproducibility of the effectiveness of defibrillation for terminating induced ventricular fibrillation using intraoperatively measured defibrillation threshold energy in patients with implanted cardioverter-defibrillator].
    Jung J; Neuzner J; Himmrich E; Vester E; Michel U; Fries R; Pitschner H; Liebrich A; Ganschow U; Heisel A
    Z Kardiol; 1998 Dec; 87(12):971-7. PubMed ID: 10025070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study.
    Bianconi L; Mennuni M; Lukic V; Castro A; Chieffi M; Santini M
    J Am Coll Cardiol; 1996 Sep; 28(3):700-6. PubMed ID: 8772759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable transvenous cardioverter-defibrillators.
    Bardy GH; Hofer B; Johnson G; Kudenchuk PJ; Poole JE; Dolack GL; Gleva M; Mitchell R; Kelso D
    Circulation; 1993 Apr; 87(4):1152-68. PubMed ID: 8462144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful implantation of cardioverter-defibrillator systems in patients with elevated defibrillation thresholds.
    Brooks R; Torchiana D; Vlahakes GJ; Ruskin JN; McGovern BA; Garan H
    J Am Coll Cardiol; 1993 Aug; 22(2):569-74. PubMed ID: 8335831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventricular pacing threshold and time to capture postdefibrillation in patients undergoing implantable cardioverter-defibrillator implantation.
    Khastgir T; Lattuca J; Aarons D; Murphy J; O'Mara V; Juanteguy J; Veltri EP
    Pacing Clin Electrophysiol; 1991 May; 14(5 Pt 1):768-72. PubMed ID: 1712951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias.
    Krol RB; Saksena S; Prakash A
    Curr Cardiol Rep; 1999 Nov; 1(4):282-8. PubMed ID: 10980855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between drugs and devices: experimental and clinical studies.
    Manz M; Jung W; Lüderitz B
    Am Heart J; 1994 Apr; 127(4 Pt 2):978-84. PubMed ID: 8160602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
    Lardoux H; Maison Blanche P; Marchand X; Canler A; Rouesnel P; Bleinc D; Péraudeau P; Scheck F
    Ann Cardiol Angeiol (Paris); 1996 Oct; 45(8):469-79. PubMed ID: 8952741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Low energy cardioversion with the implantable cardioversion defibrillator devices for treatment of ventricular tachycardia and ventricular fibrillation].
    Siebels J; Schneider MA; Kuck KH
    Z Kardiol; 1993 Nov; 82(11):683-91. PubMed ID: 8291289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-term performance of a tripolar down-sized single lead for implantable cardioverter defibrillator treatment: a randomized prospective European multicenter study. European Endotak DSP Investigator Group.
    Sandstedt B; Kennergren C; Schaumann A; Herse B; Neuzner J
    Pacing Clin Electrophysiol; 1998 Nov; 21(11 Pt 1):2087-94. PubMed ID: 9826861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between antiarrhythmic drugs and implantable cardioverter-defibrillators.
    Dougherty AH
    Curr Opin Cardiol; 1996 Jan; 11(1):2-8. PubMed ID: 8664528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.